Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.

Tremblay CL, Rouleau D, Fortin C, Toma E, Sylla M, Cyr L, Cote S, Baz M, Sampalis J, Trautman L, Sékaly RP, Boivin G.

Vaccine. 2011 Feb 4;29(7):1359-63. doi: 10.1016/j.vaccine.2010.12.023. Epub 2010 Dec 23.

PMID:
21185423
2.

Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis.

Beyer WE, Nauta JJ, Palache AM, Giezeman KM, Osterhaus AD.

Vaccine. 2011 Aug 5;29(34):5785-92. doi: 10.1016/j.vaccine.2011.05.040. Epub 2011 May 30. Review.

PMID:
21624411
3.

Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.

Walker WT, Faust SN.

Expert Rev Vaccines. 2010 Dec;9(12):1385-98. doi: 10.1586/erv.10.141. Review.

PMID:
21105775
4.

MF59 adjuvanted seasonal and pandemic influenza vaccines.

Tsai TF.

Yakugaku Zasshi. 2011;131(12):1733-41. Review.

6.

The avian influenza vaccine Emerflu. Why did it fail?

Young BE, Sadarangani SP, Leo YS.

Expert Rev Vaccines. 2015;14(8):1125-34. doi: 10.1586/14760584.2015.1059760. Epub 2015 Jun 22. Review.

PMID:
26098721
7.

Influenza vaccines: what do we want and how can we get it?

Geeraedts F, Huckriede A.

Adv Exp Med Biol. 2011;780:161-74. doi: 10.1007/978-1-4419-5632-3_13. Review.

PMID:
21842372
8.

Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations.

Burt D, Mallett C, Plante M, Zimmermann J, Torossian K, Fries L.

Expert Rev Vaccines. 2011 Mar;10(3):365-75. doi: 10.1586/erv.10.172. Review.

PMID:
21434804
9.

Influenza and HIV: lessons from the 2009 H1N1 influenza pandemic.

Sheth AN, Patel P, Peters PJ.

Curr HIV/AIDS Rep. 2011 Sep;8(3):181-91. doi: 10.1007/s11904-011-0086-4. Review.

PMID:
21710214
10.

Serologic assays for influenza surveillance, diagnosis and vaccine evaluation.

Katz JM, Hancock K, Xu X.

Expert Rev Anti Infect Ther. 2011 Jun;9(6):669-83. doi: 10.1586/eri.11.51. Review.

PMID:
21692672
11.

Pandemic H1N12009 influenza and HIV: a review of natural history, management and vaccine immunogenicity.

Cooper CL.

Curr Opin Infect Dis. 2012 Feb;25(1):26-35. doi: 10.1097/QCO.0b013e32834ef56c. Review.

PMID:
22183114
12.

[Comparison of seasonal influenza vaccines: composition and properties].

Allwinn R, Doerr HW.

Dtsch Med Wochenschr. 2011 Nov;136(45):2315-8. doi: 10.1055/s-0031-1292046. Epub 2011 Nov 2. Review. German.

PMID:
22048938
13.

Booster and higher antigen doses of inactivated influenza vaccine in HIV-infected patients.

Johnston JA, Tincher LB, Lowe DK.

Ann Pharmacother. 2013 Dec;47(12):1712-6. doi: 10.1177/1060028013507901. Epub 2013 Oct 17. Review.

PMID:
24259616
14.

Influenza vaccination in HIV-positive subjects: latest evidence and future perspective.

Ceravolo A, Orsi A, Parodi V, Ansaldi F.

J Prev Med Hyg. 2013 Mar;54(1):1-10. Review.

15.

Improving immunogenicity and effectiveness of influenza vaccine in older adults.

Cao W, Kim JH, Chirkova T, Reber AJ, Biber R, Shay DK, Sambhara S.

Expert Rev Vaccines. 2011 Nov;10(11):1529-37. doi: 10.1586/erv.11.137. Review.

PMID:
22043953
16.

Influenza vaccination in immunocompromised patients: efficacy and safety.

Zbinden D, Manuel O.

Immunotherapy. 2014;6(2):131-9. doi: 10.2217/imt.13.171. Review.

PMID:
24491087
17.

[Influenza vaccine].

Kaji M.

Nihon Rinsho. 2005 May;63 Suppl 5:595-600. Review. Japanese. No abstract available.

PMID:
15954415
18.

[Influenza vaccination in immunocompromised patients].

Klinkenberg RE, Gelinck LB.

Ned Tijdschr Geneeskd. 2014;158:A7574. Review. Dutch.

PMID:
24988164
Items per page

Supplemental Content

Write to the Help Desk